FDA requests more data for Baxter, Halozyme biotech treatment

HyQ designed for immune deficiency disorders

DEERFIELD, Ill. — The Food and Drug Administration is requesting additional data from two drug makers for a treatment for immune system disorders.

Baxter and Halozyme said the FDA wanted more data to review their application for HyQ, a combination of immune globulin and recombinant human hyaluronidase.

The companies said they would work to develop studies to provide additional data to address the agency's concerns.

 


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

Login or Register to post a comment.